The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Xilio Therapeutics Inc (NASDAQ: XLO) was $0.71 for the day, down -0.10% from the previous closing price of $0.71. In other words, the price has decreased by -$0.10 from its previous closing price. On the day, 0.51 million shares were traded. XLO stock price reached its highest trading level at $0.7251 during the session, while it also had its lowest trading level at $0.69.
Ratios:
Our analysis of XLO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 2.20.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on August 06, 2025, initiated with a Outperform rating and assigned the stock a target price of $2.
On December 21, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $36 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 16 ’25 when Shannon James Samuel bought 45,000 shares for $0.69 per share. The transaction valued at 30,870 led to the insider holds 45,000 shares of the business.
Shannon James Samuel bought 25,000 shares of XLO for $17,215 on Jun 17 ’25. The Director now owns 70,000 shares after completing the transaction at $0.69 per share. On Jun 16 ’25, another insider, Russo Rene, who serves as the PRESIDENT AND CEO of the company, bought 36,289 shares for $0.68 each. As a result, the insider paid 24,680 and bolstered with 281,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 37065232 and an Enterprise Value of -59435768. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.17. Its current Enterprise Value per Revenue stands at -1.869 whereas that against EBITDA is 1.409.
Stock Price History:
The Beta on a monthly basis for XLO is -0.04, which has changed by -0.32666665 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -9.83%, while the 200-Day Moving Average is calculated to be -7.37%.
Shares Statistics:
XLO traded an average of 748.21K shares per day over the past three months and 340310 shares per day over the past ten days. A total of 51.83M shares are outstanding, with a floating share count of 22.68M. Insiders hold about 56.79% of the company’s shares, while institutions hold 8.08% stake in the company. Shares short for XLO as of 1763078400 were 6913181 with a Short Ratio of 9.24, compared to 1760486400 on 5251586. Therefore, it implies a Short% of Shares Outstanding of 6913181 and a Short% of Float of 19.009999999999998.
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.49 and -$0.49 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.24, with 2.0 analysts recommending between -$0.18 and -$0.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 1 analysts. It ranges from a high estimate of $10.9M to a low estimate of $10.9M. As of. The current estimate, Xilio Therapeutics Inc’s year-ago sales were $1.72MFor the next quarter, 1 analysts are estimating revenue of $6.9M. There is a high estimate of $6.9M for the next quarter, whereas the lowest estimate is $6.9M.
A total of 1 analysts have provided revenue estimates for XLO’s current fiscal year. The highest revenue estimate was $41M, while the lowest revenue estimate was $41M, resulting in an average revenue estimate of $41M. In the same quarter a year ago, actual revenue was $6.34MBased on 2 analysts’ estimates, the company’s revenue will be $59.77M in the next fiscal year. The high estimate is $81.75M and the low estimate is $37.8M.
